Skip to main content
. Author manuscript; available in PMC: 2015 Aug 13.
Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

Comparison 5. HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Progression of KS 1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]